These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27398936)

  • 1. Tumor dormancy and frailty models: A novel approach.
    Rancoita PM; Valberg M; Demicheli R; Biganzoli E; Di Serio C
    Biometrics; 2017 Mar; 73(1):260-270. PubMed ID: 27398936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrence in breast cancer. Analysis with frailty model.
    Gohari MR; Mahmoudi M; Mohammed K; Pasha E; Khodabakhshi R
    Saudi Med J; 2006 Aug; 27(8):1187-93. PubMed ID: 16883450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer.
    Retsky MW; Demicheli R; Hrushesky WJ; Baum M; Gukas ID
    APMIS; 2008; 116(7-8):730-41. PubMed ID: 18834415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary and metastatic tumor dormancy as a result of population heterogeneity.
    Kareva I
    Biol Direct; 2016 Aug; 11(1):37. PubMed ID: 27549396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A quantitative insight into metastatic relapse of breast cancer.
    Hanin L; Pavlova L
    J Theor Biol; 2016 Apr; 394():172-181. PubMed ID: 26801873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour dormancy: findings and hypotheses from clinical research on breast cancer.
    Demicheli R
    Semin Cancer Biol; 2001 Aug; 11(4):297-306. PubMed ID: 11513565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A joint frailty model to estimate the recurrence process and the disease-specific mortality process without needing the cause of death.
    Belot A; Rondeau V; Remontet L; Giorgi R;
    Stat Med; 2014 Aug; 33(18):3147-66. PubMed ID: 24639014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence dynamics does not depend on the recurrence site.
    Demicheli R; Biganzoli E; Boracchi P; Greco M; Retsky MW
    Breast Cancer Res; 2008; 10(5):R83. PubMed ID: 18844974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis.
    Allan AL; Vantyghem SA; Tuck AB; Chambers AF
    Breast Dis; 2006-2007; 26():87-98. PubMed ID: 17473368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer dormancy can be maintained by small numbers of micrometastases.
    Willis L; Alarcón T; Elia G; Jones JL; Wright NA; Tomlinson IP; Graham TA; Page KM
    Cancer Res; 2010 Jun; 70(11):4310-7. PubMed ID: 20501854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival analysis of breast cancer patients using Cox and frailty models.
    Faradmal J; Talebi A; Rezaianzadeh A; Mahjub H
    J Res Health Sci; 2012 Dec; 12(2):127-30. PubMed ID: 23241526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor dormancy and cancer stem cells: two sides of the same coin?
    Kleffel S; Schatton T
    Adv Exp Med Biol; 2013; 734():145-79. PubMed ID: 23143979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures.
    Demicheli R; Retsky MW; Hrushesky WJ; Baum M
    Nat Clin Pract Oncol; 2007 Dec; 4(12):699-710. PubMed ID: 18037874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression models for infant mortality data in Norwegian siblings, using a compound Poisson frailty distribution with random scale.
    Moger TA; Aalen OO
    Biostatistics; 2008 Jul; 9(3):577-91. PubMed ID: 18304994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seeing the invisible: how mathematical models uncover tumor dormancy, reconstruct the natural history of cancer, and assess the effects of treatment.
    Hanin L
    Adv Exp Med Biol; 2013; 734():261-82. PubMed ID: 23143983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proposal for a new model of breast cancer metastatic development.
    Demicheli R; Retsky MW; Swartzendruber DE; Bonadonna G
    Ann Oncol; 1997 Nov; 8(11):1075-80. PubMed ID: 9426326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-varying coefficients in a multivariate frailty model: Application to breast cancer recurrences of several types and death.
    Mazroui Y; Mauguen A; Mathoulin-Pélissier S; MacGrogan G; Brouste V; Rondeau V
    Lifetime Data Anal; 2016 Apr; 22(2):191-215. PubMed ID: 25944225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On robustness of marginal regression coefficient estimates and hazard functions in multivariate survival analysis of family data when the frailty distribution is mis-specified.
    Hsu L; Gorfine M; Malone K
    Stat Med; 2007 Nov; 26(25):4657-78. PubMed ID: 17348081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frailties in multi-state models: Are they identifiable? Do we need them?
    Putter H; van Houwelingen HC
    Stat Methods Med Res; 2015 Dec; 24(6):675-92. PubMed ID: 22116343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cure frailty models for survival data: application to recurrences for breast cancer and to hospital readmissions for colorectal cancer.
    Rondeau V; Schaffner E; Corbière F; Gonzalez JR; Mathoulin-Pélissier S
    Stat Methods Med Res; 2013 Jun; 22(3):243-60. PubMed ID: 21632696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.